Table 2.

Base-Case Analysis*

Strategy	Cumulative Lifetime Probability, %		Cost, $	Life-Years^†	QALYs	Incremental Cost, ^$	Incremental QALYs	ICER, $/QALY^‡
Strategy	Hip Fracture	Death Due to Hip Fracture	Cost, $	Life-Years^†	QALYs	Incremental Cost, ^$	Incremental QALYs	ICER, $/QALY^‡
No test and no alendronate therapy	12.6	0.43	75 474	10.9965	6.5930	Reference^§	Reference^§	Reference^§
Test and selective alendronate therapy	12.0	0.40	75 652	10.9971	6.5957	178	0.0027	66 800
No test and universal alendronate therapy	9.9	0.33	77 153	10.9991	6.6041	1501	0.0084	178 700

ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.

The strategy was considered cost-effective if its ICER was less than $100 000 per QALY gained (32, 63).

^†

Undiscounted results.

^‡

ICER was measured by cost per QALY gained.

^§

The no test–no alendronate strategy was the reference strategy because it was the least costly, viable (nondominated) option.